RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?It's not so much bad mouthing the stock but rather the management, which is responsible for the share price direction. Like many I got into the stock because I do believe in the science but to get this to where it needs to go management has to make the correct decisions and formulate a strategy to allow it to succeed and they have failed miserably and continue to follow the same program they have used for years. One of my main concerns has always been the small number of patients in their trials. Almost always the number cannot be considered statistical significant. As an example of the correct number a recent release by ENLV on starting a PII trial and they have 120 patients. Big difference from 8, 15 and 20.